Skip to content
Human-limitedLipotropic blend for fat loss and liver health

Lipo-C

Also indexed as Lipotropic Compound, Lipo-C Injection, Lipotropic Blend

Lipo-C is a lipotropic injection blend combining several compounds—typically methionine, inositol, choline, carnitine, and B vitamins—designed to support fat metabolism and liver function. It promotes the mobilization and breakdown of fat deposits, particularly in the liver. The formulation is commonly used in weight loss programs to enhance lipolysis and improve metabolic efficiency.

Overview

Following IM or subcutaneous administration, the components achieve peak plasma concentrations within 30–60 minutes. L-Carnitine plasma levels plateau and are actively transported into skeletal muscle and cardiac tissue via OCTN2 transporters. Choline is incorporated into phosphatidylcholine or oxidized to betaine (which re-enters the methionine cycle). Cyanocobalamin is converted to methylcobalamin and adenosylcobalamin intracellularly. Methionine enters the SAM cycle, donating methyl groups and generating homocysteine (which must be remethylated by B12/folate-dependent methionine synthase — emphasizing the interdependence of blend components).

Proposed mechanism

The lipotropic agents in Lipo-C work synergistically to facilitate hepatic fat metabolism: methionine donates methyl groups for phosphatidylcholine synthesis, choline prevents hepatic steatosis by enabling VLDL export of triglycerides, and inositol modulates insulin signaling to improve glucose and lipid homeostasis. L-carnitine shuttles long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation, directly increasing the rate of fat burning. B vitamins (B1, B2, B6, B12) serve as essential cofactors in energy metabolism pathways including the citric acid cycle and fatty acid oxidation.

What the evidence supports

Human data exists but the trials are small, short-term, or not yet replicated.

Graded Human-limited

Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    The effect of L-carnitine supplementation on obesity: a systematic review and meta-analysis of randomized controlled trials

    · Obesity Reviews, Pooyandjoo M et al., doi:10.1111/obr.12436 · 2016

  2. [2]

    Choline: An Essential Nutrient for Public Health

    · Nutrition Reviews, Zeisel SH & da Costa KA, doi:10.1111/j.1753-4887.2009.00246.x · 2009

  3. [3]

    Inositol and metabolic syndrome: mechanisms and clinical applications

    · International Journal of Endocrinology, Nordio M & Proietti E · 2012

  4. [4]

    Methionine metabolism in health and cancer: a nexus of diet and precision medicine

    · Nature Reviews Cancer, Sanderson SM et al., doi:10.1038/s41568-021-00375-3 · 2021

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

ACTH 1-39

Clinical

Full-length adrenal hormone with broad receptor activity

ACTH 1-39 is the full-length, biologically active form of adrenocorticotropic hormone, a 39-amino acid peptide naturally secreted by the anterior pituitary gland. It primarily stimulates the adrenal cortex to produce cortisol, aldosterone, and adrenal androgens. Beyond adrenal signaling, ACTH 1-39 exerts direct effects on the brain, immune system, and peripheral tissues via melanocortin receptors.

0 RCT · 0 human · 0 preclinical

Immune

Adipotide (FTTP)

Animal

Targeted fat-depot destruction via vascular apoptosis

Adipotide (also called FTTP) is an experimental peptidomimetic compound designed to selectively destroy the blood supply to white adipose tissue by targeting prohibitin, a protein highly expressed on the vasculature feeding fat cells. Originally developed at MD Anderson Cancer Center, it demonstrated dramatic fat loss in obese rhesus monkeys without dietary restriction. It remains a research compound with no approved human clinical use.

0 RCT · 0 human · 0 preclinical

fat-loss

AICAR

Human-limited

AMPK activator mimicking endurance exercise effects

AICAR (Acadesine) is a nucleoside analog and potent AMPK activator that mimics the cellular energy-depletion state, triggering a cascade of metabolic adaptations including enhanced fatty acid oxidation and mitochondrial biogenesis. It has been extensively studied for its ability to improve endurance performance, insulin sensitivity, and metabolic flexibility without physical exercise. Originally developed as a cardioprotective agent, it has attracted significant interest in the performance and longevity research communities.

0 RCT · 0 human · 0 preclinical

metabolic